pre-IPO PHARMA

COMPANY OVERVIEW

HiFiBiO Therapeutics is a clinical stage global biotech pioneering a unique high-resolution translational solution (DIS®, Drug Intelligence Science) to enhance the probability of success for immunotherapies. DIS® combines unique single cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers. With DIS®, HiFiBiO gains an unprecedented understanding of immune modulation in human diseases driving a robust clinical pipeline of transformative immunotherapies. Additionally, HiFiBiO has partnered with major multinational pharmaceutical and biotech companies applying its innovative DIS® approach.


LOCATION

  • Cambridge, MA, USA
  • Paris, , France
  • Shanghai, None, China
  • Hong Kong, None, China
  • Hangzhou, None, China

  • THERAPEUTIC AREAS


    WEBSITE

    https://hifibio.com/


    CAREER WEBSITE

    https://hifibio.com/careers/


    SOCIAL MEDIA


    INVESTORS

    b-capital-group idg-capital kite-pharma lyfe-capital mirae-asset sequoia-capital


    PRESS RELEASES


    Aug 28, 2023

    Fierce Biotech Names HiFiBiO Therapeutics a “Fierce 15” Biotech Company of 2023


    Jun 23, 2023

    HiFiBiO Therapeutics Announces First Patient Dosed with HFB200301 in Combination with tislelizumab in Patients with DIS Selected Advanced Solid Tumors


    Jan 6, 2023

    HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603


    Nov 18, 2022

    HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS™ Selected Advanced Solid Tumors


    Aug 15, 2022

    HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tislelizumab in Patients with DIS™ Selected Advanced Solid Tumors


    For More Press Releases


    Google Analytics Alternative